The evolution of display technologies for antibody drug discovery
Year: 2026
Type: review
Source: Trends in biotechnology
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: American Cancer Society, Bill and Melinda Gates Foundation, Damon Runyon Cancer Research Foundation, Massachusetts General Hospital, Massachusetts Institute of Technology, University of Kansas, Ragon Institute of MGH, MIT and Harvard, Cold Spring Harbor Laboratory, Pershing Square Sohn Cancer Research Alliance, LAM Therapeutics, Mark Foundation For Cancer Research, Cancer Research UK, National Institutes of Health, National Cancer Institute, National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
Awards: G1492047154, G1576786180, G1719421551, Next Generation T cell therapies for childhood cancers (NexTGen), G2019120841, G2124495665, High-throughput identification and transcriptional analysis of autoreactive T cells in individuals with membranous nephropathy., G3202676906, G3468353038, G4809091769, Expanding CAR T cell applications through high-throughput forward- and reverse immune engineering, G6814288520, G7406926980, Dissecting the mechanisms of HIV resistance in vivo to broadly neutralizing antibodies, Potent broadly neutralizing antibody development against the HIV-1 fusion peptide epitope, Potent Antibody Protection Against P. falciparum and P. vivax Malaria
OpenAlex ID: W7162289640